Kymera Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Hello, everyone, and welcome. My name is Chris Shibutani. I'm a member of Goldman Sachs Biotech Equity Research team. We're thrilled that you can join us for the 42nd Annual Goldman Healthcare Conference. Our second virtual, hopefully, will be live pretty soon. I'm joined by my colleague, hardworking CJ Zopf. CJ, wave to your fans, who does all the smart work. I make sure, as all the clients know and make sure to hire really smart people to address my many shortcomings. But we are super excited to have Kymera Therapeutics join us today for the presentation.
I think the targeted protein degradation space has just become so much more visible, especially to the public equity investors. So we're really going to look forward to diving into understanding some of the setting that you guys are pursuing and understanding specifically about the company.
We're thrilled to have the entire C-suite basically join us here. Nobody is doing any work back in Cambridge since you're here for the next hour, the CEO, Nello
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
